April 2023 Question of the Month
In July 2022, the FDA proposed expanding the NDC to a uniform 12 numeric digit format to accommodate future needs when all options using the current formats have been exhausted. Alternative options shared by the industry have asked the FDA to consider retaining the current NDC formats and allow the use of alpha characters when all numeric options have been exhausted.
Which of the following transition types is your organization prepared for in the next 5 years?
Poll Results
August 2023 Question of the Month
What steps do you take when learning about an electronic prescribing challenge?
Root cause analysis: 0%
Compendia review: 0%
Engage a partner: 0%
All of the above: 50%
None of the above: 50%
July 2023 Question of the Month
Does your organization have a strategy for Humira biosimilar launches?
Yes, well defined: 0%
We have a framework: 50%
Waiting for clarity: 0%
No: 0%
Unaware of need: 50%
June 2023 Question of the Month
How far in advance of NDA/BLA expected approval do (or should) manufacturers begin planning their compendia submission strategy?
During Phase II Trials: 0%
Initiation of Phase III Trials: 66%
6 months prior to approval: 33%
3 months prior to approval: 0%
At time of approval: 0%
After approval: 0%
No strategy: 0%
Contact
968 Perry Highway
Pittsburgh, PA 15237
Get Directions »
Phone: (412) 635-4650
Follow/Subscribe:
